PE20141265A1 - Formulaciones liofilizadas de fgf-18 - Google Patents
Formulaciones liofilizadas de fgf-18Info
- Publication number
- PE20141265A1 PE20141265A1 PE2013002832A PE2013002832A PE20141265A1 PE 20141265 A1 PE20141265 A1 PE 20141265A1 PE 2013002832 A PE2013002832 A PE 2013002832A PE 2013002832 A PE2013002832 A PE 2013002832A PE 20141265 A1 PE20141265 A1 PE 20141265A1
- Authority
- PE
- Peru
- Prior art keywords
- concentration
- fgf
- vial
- seq
- freeze
- Prior art date
Links
- 102000003977 fibroblast growth factor 18 Human genes 0.000 title abstract 3
- 108090000370 fibroblast growth factor 18 Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 239000012931 lyophilized formulation Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 229920001993 poloxamer 188 Polymers 0.000 abstract 1
- 229940044519 poloxamer 188 Drugs 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
REFERIDO A UNA FORMULACION LIOFILIZADA ESTABLE QUE COMPRENDE: A) FACTOR DE CRECIMIENTO DE FIBROBLASTOS 18 (FGF-18), CON UNA CONCENTRACION DE 20 A 300 mcg/VIAL, EL CUAL SE SELECCIONA DE: a) UN POLIPEPTIDO QUE COMPRENDE LOS RESIDUOS DE AMINOACIDO 28-207 DE SEQ ID NO:1, b) UN POLIPETIDO QUE COMPRENDE LOS RESIDUOS DE AMINOACIDOS 28-196 DE SEQ ID NO:1 Y c) UN POLIPEPTIDO QUE COMPRENDE LA SEQ ID NO:2; B) UN TAMPON QUE MANTIENE UN pH ENTRE 6 Y 8, TAL COMO FOSFATO, CON UNA CONCENTRACION DE 5 A 100 mM; C) UN TENSIOACTIVO DE POLOXAMERO, TAL COMO POLOXAMERO 188, CON UNA CONCENTRACION DE 0,1 A 0,4 mg/VIAL; Y D) UN AZUCAR COMO AGENTE ESTABILIZANTE, TAL COMO SACAROSA, CON UNA CONCENTRACION DE 10 A 60 mg/ VIAL. REFERIDO ADEMAS A UN METODO PARA PRODUCIR LA FORMULACION LIOFILIZADA. DICHA FORMULACION ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS DE LOS CARTILAGOS TALES COMO OSTEOARTRITIS O LESION DE LOS CARTILAGOS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11170437 | 2011-06-17 | ||
| US201161499216P | 2011-06-21 | 2011-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141265A1 true PE20141265A1 (es) | 2014-09-29 |
Family
ID=47356563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002832A PE20141265A1 (es) | 2011-06-17 | 2012-06-15 | Formulaciones liofilizadas de fgf-18 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9326944B2 (es) |
| EP (2) | EP2720710B1 (es) |
| JP (1) | JP5981538B2 (es) |
| KR (1) | KR102019520B1 (es) |
| CN (2) | CN107715104A (es) |
| AR (1) | AR086956A1 (es) |
| AU (1) | AU2012268987B2 (es) |
| BR (1) | BR112013032400B1 (es) |
| CA (1) | CA2836667C (es) |
| CL (1) | CL2013003618A1 (es) |
| CO (1) | CO6940377A2 (es) |
| CY (1) | CY1117933T1 (es) |
| DK (1) | DK2720710T3 (es) |
| EA (1) | EA024937B1 (es) |
| EC (1) | ECSP14013157A (es) |
| ES (1) | ES2575732T3 (es) |
| HR (1) | HRP20160566T1 (es) |
| HU (1) | HUE028355T2 (es) |
| IL (1) | IL229977A (es) |
| MX (1) | MX338017B (es) |
| MY (1) | MY170630A (es) |
| PE (1) | PE20141265A1 (es) |
| PH (1) | PH12013502529A1 (es) |
| PL (1) | PL2720710T3 (es) |
| PT (1) | PT2720710E (es) |
| RS (1) | RS54875B1 (es) |
| SG (1) | SG195021A1 (es) |
| SI (1) | SI2720710T1 (es) |
| TW (1) | TWI527590B (es) |
| UA (1) | UA113174C2 (es) |
| WO (1) | WO2012172072A1 (es) |
| ZA (1) | ZA201308698B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| NZ721597A (en) | 2013-12-24 | 2022-07-01 | Ares Trading Sa | Fgf-18 formulation in alginate/collagen hydrogels |
| WO2016120387A1 (en) | 2015-01-29 | 2016-08-04 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| BR112018002404A2 (pt) * | 2015-08-13 | 2018-09-18 | Merck Patent Gmbh | composição de combinação compreendendo composto de fgf-18 |
| LT3688468T (lt) | 2017-09-29 | 2022-06-27 | Merck Patent Gmbh | Uždegiminiai biožymenys, skirti atsako į fgf-18 junginį numatymui |
| EP3687558B1 (en) | 2017-09-29 | 2022-03-16 | Merck Patent GmbH | Metabolic biomarkers for predicting responsiveness to fgf-18 compound |
| EP3706710B1 (en) * | 2017-11-10 | 2024-04-10 | Novartis AG | Extended release formulations for intra-articular applications |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
| CN109836487B (zh) * | 2019-03-01 | 2022-06-17 | 重庆派金生物科技有限公司 | 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用 |
| CN112121150A (zh) * | 2019-06-24 | 2020-12-25 | 杭州生物医药创新研究中心 | 一种成纤维细胞生长因子10冻干粉 |
| PT4034115T (pt) * | 2019-09-25 | 2025-03-25 | Lumosa Therapeutics Co Ltd | Composição farmacêutica compreendendo conjugado péptido trombolítico-tetra-hidroisoquinolina |
| CN113304063A (zh) * | 2021-04-23 | 2021-08-27 | 四川省恩乐生物工程有限公司 | 一种用于肌肤美容抗衰老的组合物及其制备方法 |
| CN117338705A (zh) * | 2022-06-28 | 2024-01-05 | 中国医学科学院药物研究所 | 一种含有奥司他韦的粉液双室袋制剂及其制备方法 |
| CN118310835B (zh) * | 2024-04-16 | 2025-04-11 | 杭州百凌生物科技有限公司 | 一种质控品冻干粉及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217954A (en) * | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
| GB9015824D0 (en) | 1990-07-18 | 1990-09-05 | Erba Carlo Spa | Stable pharmaceutical compositions containing a fibroblast growth factor |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US20010056066A1 (en) * | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
| UA75316C2 (uk) * | 1996-10-16 | 2006-04-17 | Займодженетікс, Інк. | Гомологи з фактором росту фібробласта |
| CN1184673A (zh) * | 1996-12-13 | 1998-06-17 | 中国医科大学 | Fgf粗提多肽生长因子混合物及其提取工艺 |
| JP2002527401A (ja) * | 1998-10-13 | 2002-08-27 | カイロン コーポレイション | Ｆｇｆの脈管形成的に有効な単位用量および投与方法 |
| ATE539157T1 (de) | 1999-12-02 | 2012-01-15 | Zymogenetics Inc | Methoden welche auf zellen zielen, die die fibroblasten wachtumsfaktor-rezeptoren-3 oder -2 exprimieren |
| CN1303714A (zh) * | 2000-01-13 | 2001-07-18 | 重庆多泰制药有限公司 | Ii型胶原蛋白口服胃溶制剂 |
| WO2002017956A2 (en) * | 2000-08-31 | 2002-03-07 | Chiron Corporation | Stabilized fgf formulations containing reducing agents |
| CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
| AU2003279835B2 (en) * | 2002-10-07 | 2009-09-10 | Zymogenetics, Inc. | Methods of administering FGF18 |
| KR101235507B1 (ko) * | 2003-02-28 | 2013-02-20 | 추가이 세이야쿠 가부시키가이샤 | 단백질을 함유하는 안정화 제제 |
| EP1750750B1 (en) * | 2004-06-01 | 2012-02-01 | Ares Trading S.A. | Method of stabilizing proteins |
| US20080176790A1 (en) * | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| DK1828239T3 (da) | 2004-12-10 | 2011-12-19 | Zymogenetics Inc | FGF18-produktion i prokaryote værter |
| CN101584858A (zh) * | 2005-12-20 | 2009-11-25 | 布里斯托尔-迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
| JP4729740B2 (ja) * | 2006-01-11 | 2011-07-20 | 独立行政法人産業技術総合研究所 | 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物 |
| HRP20120994T1 (hr) | 2006-02-07 | 2012-12-31 | Shire Human Genetic Therapies, Inc. | Stabilizirana smjesa glukocerebrozidaze |
| HRP20120643T1 (hr) | 2006-08-25 | 2012-08-31 | Ares Trading S.A. | Liječenje poremećaja hrskavice sa fgf-18 |
| CN101663046B (zh) * | 2007-03-30 | 2017-07-28 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
| CA2682147C (en) * | 2007-03-30 | 2017-08-08 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| CN101181280B (zh) * | 2007-11-23 | 2010-07-14 | 深圳万乐药业有限公司 | 吡柔比星冻干制剂及其制备方法 |
| KR101247418B1 (ko) * | 2007-12-21 | 2013-03-25 | 에프. 호프만-라 로슈 아게 | 항체 제형 |
| TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
-
2012
- 2012-06-11 TW TW101120864A patent/TWI527590B/zh active
- 2012-06-15 MX MX2013014894A patent/MX338017B/es active IP Right Grant
- 2012-06-15 PE PE2013002832A patent/PE20141265A1/es not_active Application Discontinuation
- 2012-06-15 PL PL12728509.6T patent/PL2720710T3/pl unknown
- 2012-06-15 PT PT127285096T patent/PT2720710E/pt unknown
- 2012-06-15 CN CN201710984784.XA patent/CN107715104A/zh active Pending
- 2012-06-15 KR KR1020137034615A patent/KR102019520B1/ko active Active
- 2012-06-15 AR ARP120102140A patent/AR086956A1/es not_active Application Discontinuation
- 2012-06-15 EA EA201490032A patent/EA024937B1/ru not_active IP Right Cessation
- 2012-06-15 RS RS20160453A patent/RS54875B1/sr unknown
- 2012-06-15 HU HUE12728509A patent/HUE028355T2/en unknown
- 2012-06-15 WO PCT/EP2012/061495 patent/WO2012172072A1/en not_active Ceased
- 2012-06-15 SI SI201230600A patent/SI2720710T1/sl unknown
- 2012-06-15 EP EP12728509.6A patent/EP2720710B1/en active Active
- 2012-06-15 ES ES12728509.6T patent/ES2575732T3/es active Active
- 2012-06-15 CN CN201280029683.2A patent/CN103619347A/zh active Pending
- 2012-06-15 JP JP2014515216A patent/JP5981538B2/ja active Active
- 2012-06-15 EP EP16161448.2A patent/EP3056211A1/en not_active Withdrawn
- 2012-06-15 BR BR112013032400-7A patent/BR112013032400B1/pt active IP Right Grant
- 2012-06-15 MY MYPI2013702439A patent/MY170630A/en unknown
- 2012-06-15 HR HRP20160566TT patent/HRP20160566T1/hr unknown
- 2012-06-15 CA CA2836667A patent/CA2836667C/en active Active
- 2012-06-15 UA UAA201314452A patent/UA113174C2/uk unknown
- 2012-06-15 AU AU2012268987A patent/AU2012268987B2/en active Active
- 2012-06-15 DK DK12728509.6T patent/DK2720710T3/en active
- 2012-06-15 PH PH1/2013/502529A patent/PH12013502529A1/en unknown
- 2012-06-15 US US14/126,937 patent/US9326944B2/en active Active
- 2012-06-15 SG SG2013085162A patent/SG195021A1/en unknown
-
2013
- 2013-11-20 ZA ZA2013/08698A patent/ZA201308698B/en unknown
- 2013-12-17 IL IL229977A patent/IL229977A/en active IP Right Grant
- 2013-12-17 CL CL2013003618A patent/CL2013003618A1/es unknown
-
2014
- 2014-01-15 CO CO14006968A patent/CO6940377A2/es unknown
- 2014-01-17 EC EC2014013157A patent/ECSP14013157A/es unknown
-
2016
- 2016-04-26 US US15/138,240 patent/US20160228374A1/en not_active Abandoned
- 2016-06-22 CY CY20161100564T patent/CY1117933T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141265A1 (es) | Formulaciones liofilizadas de fgf-18 | |
| ECSP23041058A (es) | Formulación subcutánea de anticuerpo anti-her2 | |
| PE20141159A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| PE20130589A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a | |
| SG144075A1 (en) | Protein stabilization formulations | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| ECSP12011722A (es) | Formulaciones farmacéuticas muy concentradas que comprenden un anticuerpo anti-cd20 | |
| CL2011003003A1 (es) | Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. | |
| MX2019010598A (es) | Composicion farmaceutica que comprende selexipag. | |
| AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
| MX349992B (es) | Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe. | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| AR077234A1 (es) | Composicion de factor vii. procedimiento para prepararla | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| BR112012006283A2 (pt) | formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte | |
| PE20120788A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos | |
| BR112016006455A2 (pt) | ?formulação de conjugado de hormônio de crescimento humano de ação prolongada? | |
| MX2016012447A (es) | Formulaciones de factor ix liofilizadas. | |
| CO2019003876A2 (es) | Formulación farmacéutica parenteral que contiene ácido carglúmico | |
| AR086672A1 (es) | Formulaciones de furina recombinante | |
| AR083006A1 (es) | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas | |
| AR094481A1 (es) | Formulaciones de albu-bche (albúmina-butirilcolinesterasa), preparación y sus usos | |
| PE20170699A1 (es) | Uso del acido neridronico o de su sal para el tratamiento de la osteoartrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |